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Abstract
Background: Governments and donors all over Africa are searching for sustainable, affordable and cost-effective
ways to improve the quality of malaria case management. Widespread deficiencies have been reported in the
prescribing and counselling practices of health care providers treating febrile patients in both public and private
health facilities. Cameroon is no exception with low levels of adherence to national guidelines, the frequent
selection of non-recommended antimalarials and the use of incorrect dosages. This study evaluates the
effectiveness and cost-effectiveness of introducing two different provider training packages, alongside rapid
diagnostic tests (RDTs), designed to equip providers with the knowledge and practical skills needed to effectively
diagnose and treat febrile patients. The overall aim is to target antimalarial treatment better and to facilitate
optimal use of malaria treatment guidelines.
Methods/Design: A 3-arm stratified, cluster randomized trial will be conducted to assess whether introducing
RDTs with provider training (basic or enhanced) is more cost-effective than current practice without RDTs, and
whether there is a difference in the cost effectiveness of the provider training interventions. The primary outcome
is the proportion of patients attending facilities that report a fever or suspected malaria and receive treatment
according to malaria guidelines. This will be measured by surveying patients (or caregivers) as they exit public and
mission health facilities. Cost-effectiveness will be presented in terms of the primary outcome and a range of
secondary outcomes, including changes in provider knowledge. Costs will be estimated from a societal and
provider perspective using standard economic evaluation methodologies.
Trial Registration: ClinicalTrials.gov: NCT00981877
Keywords: Cost-effectiveness, malaria, Rapid Diagnostics tests (RDTs)
Background
Governments and donors all over Africa are searching for
sustainable, affordable and cost-effective ways to improve
the quality of malaria case management. Widespread
deficiencies have been reported in the prescribing and
counselling practices of providers (by which we mean
health workers) responsible for treating febrile patients
attending public and private facilities [1-8]. Similar pro-
blems have been reported in Cameroon where malaria
accounts for 35%-40% of all deaths, 50% of morbidity
among children under the age of five, 40%-45% of medi-
cal consultations and 30% of hospitalizations [9,10].
Despite widespread availability of malaria testing using
microscopy in public and private facilities in Cameroon
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tion (WHO) recommending parasitological confirmation
of suspected malaria cases in all patients before treat-
ment where testing facilities are available [11], sympto-
matic diagnosis of malaria remains routine in more than
50% of consultations [12]. There is, however, increasing
interest in scaling up the use of rapid diagnostic tests
(RDTs) to expand access to parasitological diagnosis and
improving malaria case management. The Government
of Cameroon is piloting the introduction of RDTs into
communities in 50 health districts in the national terri-
tory [13]. This policy initiative is based on the premise
that making RDTs available will make it quicker and
easier to test and in turn, promote the rational use of
artemisinin-based combination therapy (ACT).
The appeal of RDTs lies in their high specificity and
sensitivity. They are relatively simple to use compared
with microscopy and do not require specialised skills or
laboratory equipment and reagents that are often una-
vailable in rural or resource poor settings [14]. RDTs are
also seen as the solution to malaria over-diagnosis, a
practice that can be costly [15] and result in poorer
health through delays in access to treatment of the cor-
rect diagnosis and repeated treatment seeking costs [16].
Misdiagnosis may also contribute to increasing antima-
larial drug pressure and thus resistance, thereby speeding
up the ineffectiveness of available and affordable drugs
[17]. Hence there is both a human and an economic case
for introducing RDTs compared with existing presump-
tive treatment. However, in order for the full benefits of
RDTs to be realised, supporting interventions that encou-
rage health workers to deliver treatment that is consistent
with malaria guidelines are likely to be needed.
The diagnosis and subsequent treatment of malaria is a
complex decision making process [18]. Interventions
must be sympathetic to a wide range of issues that provi-
ders face including a lack of training in the use of RDTs
especially among more junior staff [19], a distrust of test
results particularly negative ones [6,20,21], lack of alter-
native drugs with which to treat fever patients [19,22]
and patient demand for inappropriate medicines
[8,19,23]. All of these issues have been shown to affect
whether a malaria test is done and in turn acted upon.
If diagnostic and prescribing practices of providers are
to be improved through the large-scale procurement and
deployment of RDTs and ACTs in countries such as
Cameroon, some level of supporting interventions are
likely to be needed, or the intended benefits of these
investments may be seriously undermined. The WHO
recommends that a number of conditions are in place
before integrating and scaling up the use of RDTs in
malaria control and primary health care services includ-
ing provider training, monitoring how the test is used
and the establishment of clear guidelines that incorporate
a diagnosis and treatment algorithm that includes RDTs
[24]. To date, the most cost-effective composition of
training for providers is not known. There are arguments
for both a basic introduction to the tests that will require
few resources to implement, and for a more comprehen-
sive programme that not only equips providers with the
knowledge of the malaria guidelines and skills to use
RDTs, but also strives to improve the quality of malaria
case management by supporting providers to change
their practice and manage patient expectations, especially
when the malaria test is negative. This study will use a
cluster randomized controlled trial to help identify, in
routine health facility scenarios, which of these options is
most effective and cost-effective in equipping providers
with the knowledge and practical skills needed to effec-
tively diagnose and treat febrile patients. It is important
to compare these options for supporting RDT introduc-
tion with current practice in the absence of RDTs but
where microscopy is widely available, in order to identify
whether there is a value to introducing these new tests
at all.
A strength of this trial is that the chosen provider
interventions target several specific problems identified
through our own formative research that undermine the
implementation of malaria treatment guidelines in
Cameroon. Between May and November 2009, a cross-
sectional cluster survey and series of focus group discus-
sions were conducted to understand current practices in
delivering malaria treatment in the two sites targeted for
the evaluation. It was revealed that all mission and
almost 90% of public health facilities have microscopy
testing available, though only about a third used it. Qui-
nine, which should be reserved only for cases of severe
malaria, was often used for the treatment of uncompli-
cated malaria. Factors affecting providers’ choice of
treatment appeared to be broader than simple consid-
eration of the test result, with many patients receiving
antimalairals they do not need. Some of the issues iden-
tified were unique to the local setting while others
reflect problems experienced across the country and
elsewhere. A description of the methods and results of
the formative research have been published elsewhere
[12,25].
Finally, this study also makes an important contribu-
tion to the pursuit of efficiency. While evaluations of a
wide range of provider training interventions have been
reported in the literature [26-28] using an equally wide
range of methods, few of these enable the assessment of
the relative value for money of these interventions. This
study will provide much needed information on the
cost-effectiveness of the selected provider training inter-
ventions which will aid health care planners in their
decisions over how to allocate scarce health care
resources.
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This study is a 3-arm stratified cluster randomised con-
trolled trial across 47 health facilities in two areas of
Cameroon. The intervention is being delivered at the facil-
ity level and therefore this will be the unit of randomisa-
tion with study site as the stratum. Outcomes will be
assessed through exit interviews with patients as well as
health facility surveys. Economic and financial costs will
also be measured to enable the calculation of incremental
cost-effectiveness ratios. Ethical approval for this study
was obtained from the Cameroon National Ethics Com-
mittee and the London School of Hygiene and Tropical
Medicine.
Study area and participants
The two study sites are Yaoundé and Bamenda in the
Centre and Northwest regions respectively. The Bamenda
study site consists of an urban health district and seven
rural health districts that lie within a 21 km radius. It is
predominantly an English and pidgin-English speaking
region with an estimated population of 2 million. The
Yaoundé study site encompasses seven urban health dis-
tricts and has an estimated population of 2.5 million that
is predominantly French-speaking.
Although both study sites lie within the forest ecological
zone of Cameroon favorable for the development of the
Plasmodium parasite and Anopheles vector, they have dif-
ferent climatic patterns. The Yaoundé study site has two
main seasons: the long wet season that lasts from February
to November (with more intense rains between September
and November) and a short dry season from December to
January. Transmission in this site is perennial with an
inoculation rate of over 100 infected bites per person per
month. The Bamenda study site is characterized by one
long rainy season (March - October) of intense transmis-
sion with inoculation rates of 20 infected bites per person
per month. In 2004, the forest ecological zone accounted
for 40.6% of the total malaria morbidity (40.1%) recorded
in the general population [29,30].
All public and mission health facilities have been enum-
erated and GPS mapped. Health facilities were informed
of the proposed study and asked to give verbal consent
before GPS coordinates were obtained. They include pub-
lic district hospitals and health centres, mission hospitals
and mission health centres. The health centres are staffed
by nurses and sometimes medical doctors. Each of these
health facilities has a propharmacy with a pharmacy atten-
dant and a laboratary for simple diagnostic procedures
including microscopy testing.
Facilities will be selected at random within each stratum
from those that are not included in the Government pilot
roll-out of RDTs, do not solely offer specialist services, see
4 or more febrile patients per day, and are accessible by
road throughout the wet season. Selected facilities will be
asked to give written consent prior to randomisation. If
facility-level consent is not provided replacement facilities
will be randomly selected from the remaining list of
eligible facilities.
Contamination may occur if providers that have
received basic or enhanced training meet to discuss
their training or if they meet with providers from the
control facilities. This may result in information or stra-
tegies being shared, the effect of the intervention
spreading to control clusters and possible dilution of
differences between treatment arms. In order to reduce
the risk of contamination, the different intervention and
control facilities are separated by a buffer area. Specifi-
cally, facilities within the same health area will be
selected if they are ≥ 2k mf r o ma n o t h e rf a c i l i t yi n
Bamenda and ≥ 1 km in Yaoundé.
All patients (or their caregiver) attending the health
facilities will be approached on exit for consent to parti-
cipate in an exit survey and screened for their eligibility.
Patients will be eligible if they are present at the facility
and they (or their caregiver) report seeking treatment
for fever or suspected malaria. Patients will be excluded
if they are pregnant, less than 6 months old or have
signs and symptoms of severe malaria. All providers that
are responsible for diagnosis and treatment of suspected
cases of malaria will be eligible to participate in the pro-
vider survey.
Interviewers will explain to all participants that invol-
vement in the study is voluntary and they have the right
to withdraw at any point in time and ask any questions.
Information about the study will be read to all partici-
pants and provided in hard copy. All participants will be
asked if they give their consent to take part in the study
and if so, asked to sign the standard consent form.
Interventions
Health facilities will be randomised to either current
practice or one of the two provider interventions. The
basic intervention is the introduction of RDTs with basic
provider training on malaria diagnosis and treatment
while the enhanced intervention will be the introduction
of RDTs with enhanced provider training. The enhanced
training covers the material in the basic training and also
strives to improve the quality of care by supporting pro-
viders to adapt their practice by encouraging further dis-
cussion of the malaria guidelines, interactive self-
awareness, improve their ability to communication with
patients and colleagues.
Supply of RDTs
Facilities randomised to either the basic intervention or
the enhanced intervention will be supplied with RDTs
for use in diagnosing malaria. The RDT that will be
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detect P. falciparum, P.vivax, P. malariae or P.ovale.
T h i st e s tw a sc h o s e ni nc o n j u nction with the National
Malaria Control Programme and is reported to have a
minimum detection rate of for P. falciparum of 97.5%
even at low levels of parasitaemia (200 parasites/μl) [31].
The supply of RDTs is intended to be relatively stable
in order to assess the impact of the two provider inter-
v e n t i o n si nt h ec o n t e x to far e l i a b l es u p p l ys y s t e m .
RDTs will be provided by the study team, free of charge,
on a four-weekly rotation basis. Estimates of RDTs
required will be determined in discussion with the facil-
ity head and based on routine records of the number of
febrile patients that a facility can expect during a month
(taking into account seasonal variations). Members of
the research team will deliver RDTs to the facilities at
the start of each month with the option for replenish-
ment between delivery dates. Stock management records
will be kept by the study team to monitor the distribu-
tion of these RDTs.
Facilities will be requested not to charge for the use of
an RDT in children <5 years, but will be able to charge
a token fee of at most 100CFA (0.2USD) for all patients
above 5 years of age. Currently there is no national pol-
icy for the cost of RDTs in health facilities. Facilities are
routinely supplied with ACTs and we will not alter the
current distribution of medicines by the government or
mission authorities. Our formative research found that
more than 80% of public and mission facilities had
ACTs in stock. In the analysis we will take into account
that stock-outs of ACTs would prevent patients from
receiving ACTs by also considering a secondary out-
come which allows either prescription or receipt of an
ACT.
Basic Provider Training (BT)
Facilities randomised to the basic intervention will be
supplied RDTs and receive basic provider training on
malaria diagnosis and treatment. This training is
intended to mimic the style of workshop that is routinely
implemented as in-service health worker training. The
training will be conducted over one day and contain
three training modules: 1) Malaria Diagnosis; 2) Rapid
Diagnostic Testing; 3) Malaria Treatment. Together
these three training modules will provide health workers
with the knowledge and skills on why malaria testing is
recommended, how to use an RDT, the treatment algo-
rithm and details contained in the malaria guidelines.
The malaria guidelines state how confirmed cases of
uncomplicated malaria should be treated, including
advice on dosing and treatment regimens for different
types of ACT. The training also provides advice on other
causes of febrile illness which should be investigated if
the malaria test is negative. The module on RDTs
includes a practical session in which all health workers
will get hands-on experience of the steps involved in
using an RDT.
The training will be conducted in conference halls of
health districts located in both study sites. The following
types of providers will be invited to the training: medical
doctors, nurses, laboratory technicians and pharmacy
attendants. Each facility will be invited to select 3 provi-
ders to attend the training. The training will be con-
ducted jointly by medical doctors, representatives of the
national malaria control programme and the research
team. The trainers will receive extensive briefing by the
research team and given a trainer’s manual which pro-
vides detail of the material for each module and how it
should be delivered. The training manual also includes
standardized power-point presentations. In addition, the
trainers will be trained in presentation and communica-
tions skills.
Each basic training workshop will train 25-30 provi-
ders. The training primarily takes a didactic seminar
style in which the trainer delivers the training material,
though there is scope for questions and discussion. A
participant’s training manual will be given to providers
that attend the training course and includes all essential
reference material including the malaria treatment
guidelines. Participants will also be provided with job
aids for RDTs and a treatment algorithm to be placed
on their tables while in their health facilities.
All participants of the basic training will be strongly
encouraged to train others at their facilities using copies
of the training materials including manuals, copies of
presentations and table top flip charts. This will not be
mandatory or enforced, but as an incentive only those
that train their colleagues will be given a certificate of
completion.
Enhanced Provider Training (ET)
All facilities randomized to the enhanced intervention
will be supplied RDTs and receive enhanced provider
training. Enhanced provider training covers all the mate-
rial contained in the basic provider training but also
additional material targeting improvements in quality of
care. The enhanced provider training will last for a total
of three days (one day on basic training modules and an
extra two days for the additional material). This training
is more resource-intensive than routine in-service train-
ing, but intends to tackle some of the ingrained factors
affecting health worker prescribing in relation to
malaria, as identified in Cameroon and elsewhere.
The enhanced provider training contains three addi-
tional training modules: 4) Adapting to Change; 5) Pro-
fessionalism; 6) Communicating Effectively. A specific
focus of these modules is to address challenges posed by
RDTs for interactions between the health workers and
patients. The modules take an interactive and supportive
approach to training with the majority of the material
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cises in each module based on games and puzzles, testi-
monials on the use of RDTs, self-developed participatory
drama and role-playing. In these additional modules the
role of the trainer is to direct and facilitate the learning
process rather than provide technical information. The
participants will be given training materials to accom-
pany these modules.
The adapting to change module seeks to provide health
workers with the opportunity to reflect and discuss the
clinical guidelines, and learn from others. This module
includes testimonials on the use of RDTs and participants
have the opportunity to reflect on and discuss the recom-
mendations in the malaria guidelines. As well as small
group discussions, the module has a card game that 4-6
participants can play. Participants take turn in collecting
cards and achieve a point when they present three cards
that show a patient has received treatment in line with
guidelines. This can be achieved by presenting a ‘patient
with fever’ card accompanied by a ‘RDT positive’ card and
an ‘ACT’ card, or alternatively by presenting a ‘patient
with fever’ card accompanied with an ‘RDT negative’ card
and a ‘further investigation’ card. The game ends when a
participant has treated five patients in line with the guide-
lines and scored five points.
The professionalism module appeals to the providers to
identify and agree what values and behaviours are impor-
tant when providing care. It also emphasises the impor-
tance of working as a team and supporting each other.
The module includes an exercise that considers real-life
scenarios that may interrupt the process of care and parti-
cipants are encouraged to develop strategies for managing
these situations.
The final module focuses on improving the providers’
skills in communicating with patients. It starts by reflect-
ing on what patients think about malaria and malaria
treatment. The module also focuses on managing patient
expectations and allows providers to develop skills and
techniques for explaining to patients why they should be
tested, and also for the situation when the test is negative
and an antimalarial should not be prescribed. Dramas are
developed and acted out by the participants with the sup-
port of the facilitators to help providers understand the
consequences for patients when they are not prescribed
the recommended medicine and what alternative courses
of action may be pursued.
As with the basic training, all participants of the
enhanced training will be strongly encouraged to train
others at their facilities and will only be given a certifi-
cate of completion once this has been undertaken.
Control Arm
The control arm represents current practice. Providers
in these facilities will not receive RDTs or training as
part of the study and are expected to continue to
provide usual medical care for fever patients attending
their facility. Our formative research showed that 90%
of public health facilities and all mission health facilities
in the study sites had microscopy testing, though none
had RDTs.
Objectives
The primary objective is to evaluate the effectiveness
and cost-effectiveness of:
￿ Basic intervention (i.e. introducing RDTs with
basic provider training) compared to current
practice;
￿ Enhanced Intervention (i.e. introducing RDTs with
enhanced provider training) compared to current
practice; and
￿ Enhanced Intervention compared to Basic
Intervention.
Secondary objectives include:
￿ To describe the process of implementing the inter-
ventions including participant assessment of the
training received;
￿ To document health worker knowledge and ability
to test and appropriately treat patients with sus-
pected malaria;
￿ To evaluate patient satisfaction with the quality of
care received at the health facility;
￿ To calculate the economic and financial costs of
the provider interventions;
￿ To assess whether the effectiveness and cost-effec-
tiveness of the interventions varies according to
urban/rural residence or socioeconomic status of the
patient.
Hypotheses
￿ Basic Intervention is more effective in improving
the treatment and diagnosis of malaria (measured by
adherence to malaria treatment guidelines) than cur-
rent practice.
￿ Enhanced Intervention will be more effective in
improving the treatment and diagnosis of malaria
compared to current practice and compared to Basic
Intervention.
￿ Basic Intervention is more cost-effective in improv-
ing the treatment and diagnosis of malaria compared
to current practice.
￿ Enhanced Intervention is more effective and more
costly compared to Basic Intervention.
The relationship between the study hypotheses and
outcomes are summarised in Figure 1.
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Primary outcome
The primary outcome is the proportion of patients attend-
ing facilities that report a fever or suspected malaria and
receive treatment according to malaria guidelines. The
corresponding measure of cost-effectiveness is the cost per
febrile patient that receives treatment according to the
malaria guidelines.
Treatment according to the malaria guidelines is a
composite endpoint requiring that:
￿ Febrile patients should be tested for malaria, using
either microscopy or an RDT
￿ The patient should receive an ACT if he/she has a
positive malaria test result
￿ The patient should not receive an antimalarial if
he/she has a negative malaria test result
The outcome measure is summarized in Figure 2.
Secondary outcomes
Secondary outcomes include:
￿ Proportion of febrile patients that are tested for
malaria
￿ Proportion of febrile patients receiving an antima-
larial that receive an ACT
￿ Proportion of febrile patients receiving an ACT
that receive the correct dose for their age
￿ Proportion of febrile patients receiving an ACT
that accurately report how to take the medicine
￿ Proportion of febrile patients that report they are
satisfied with the care received
￿ Proportion of HWs that report they were satisfied
with the training received
￿ Proportion of HWs that know ACT should be
given if the malaria test is positive and that an anti-
malarial should not be given if the malaria test is
negative
Figure 1 Effect of Provider Interventions on the Treatment Received by Patients.
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should be tested for malaria
￿ Proportion of HWs that know how to identify
positive, negative and invalid malaria RDT results
￿ Proportion of HWs that know the correct dose of
the first-line ACT in an adult and in a child aged 2
years
￿ Total cost of the provider interventions and the
cost per HW attending the BT and ET
Secondary outcomes related to patients will also be
reported in terms of their urban/rural residence and
socioeconomic status.
Evaluation design
The evaluation of the intervention will use data col-
lected in a patient exit survey, a register of malaria tests
conducted by the provider during patient consultations,
a provider survey, documentation of the intervention
process, costing of the intervention activities and lastly,
independent testing of malaria by the study team (see
‘quality assurance’). The patient exit survey will be
administered before the provider survey to ensure that
the treatment received by patients is not influenced by
the content of the provider questionnaire. Each of these
is described below.
Patient exit survey
The primary outcome will be measured through an inter-
viewer-administered patient exit survey. Data collection
will commence three months after the intervention has
been implemented. The three-month lag in the data col-
lection is to ensure that the effect measure reflects treat-
ment practices in the medium-term. In the short-term it is
recognised that it is possible that the effect is overstated
because health workers may change practices initially but
revert to past behaviours over time, or that the effect is
understated because it takes time for the training to have
an effect as some health workers are hesitant and want to
learn from the experience of the early-adopters. The sur-
vey data collection will take up to two months and will be
organized such that the data will show the effect of the
intervention over this time period by establishing a maxi-
mum number of patients that can be surveyed each week.
The research team will recruit field workers and pro-
vide training over a week on all aspects of data collec-
tion related to the patient exit survey. The training will
include a practical assessment of their ability to provide
information to respondents about the survey, obtain
consent and administer the questionnaire. The research
team will supervise the field workers and will accom-
pany the field worker at the start of data collection to
obtain consent from the head of the facility and ensure
the fieldworker adheres to the standard operating proce-
dures. Supervisory visits to monitor the performance of
the field workers will take place at least once each week
during the data collection period.
The patient exit questionnaire is designed to collect
information about the patient’s experience of seeking
treatment and has been piloted a selected facilities in
the study site. The questionnaire contains the following
ten modules:
A. Background Information, Consent and Screening
Questions
B. Details of the Respondent and/or Patient
C. Reasons for attendance
D. Consultation and diagnosis
E. Treatment prescribed and received
F. Patient satisfaction and knowledge of malaria
Figure 2 Primary outcome measure.
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H. Household characteristics
I. Malaria test completed by the study team (in sub-
sample of patients)
J. Malaria test completed by health workers (from reg-
ister of malaria tests at facility)
Register of malaria tests conducted
The patient exit questionnaire will be supplemented by
a register of malaria tests at each participating health
facility because patients may not always know if they
were tested for malaria and the result of the malaria
test. With consent from the head of the facility, health
workers responsible for conducting malaria tests will be
asked to keep a register of all malaria tests undertaken.
The following data will be collected: details of the
patient, availability of microscopy and RDT, method of
test conducted, test result and the provider that con-
ducted the test. At each facility the field workers will
collect the register of malaria tests at least once each
week and will use the patient’s name, gender, age, date
of visit to identify the patients that completed the survey
and record the details in Section J of the questionnaire.
Provider Survey
T h er e s e a r c ht e a mw i l la d m i n i s t e rap r o v i d e rs u r v e yt o
all providers responsible for the diagnosis and treatment
of suspected cases of malaria. Providers are eligible to
participate if their responsibilities include any of the fol-
lowing activities: taking patient signs and symptoms,
undertaking diagnostic tests, prescribing or dispensing
medication. Written informed consent will be obtained
before commencing the survey.
The provider survey has been designed to collect data on
the providers’ characteristics, knowledge and preferences
for diagnosing and treating malaria and details of the
resources available at the health facility. The survey will be
piloted with providers at facilities that are not participating
in the study. The questionnaire contains the following
modules (of which A-B are completed by all providers and
C-G are completed once for each facility):
A. Background information, consent and screening
questions
B. Health worker characteristics and treatment
practices
C. Details of the health facility
D. Management and procurement of drugs
E. Availability of RDTs
F. Availability of Antimalarials
G. List of all health workers that are involved in
diagnosis or treatment
Documentation of the Intervention Process
The implementation of the malaria training workshops
delivered to health workers will be documented. Details
of all participants attending the training course will be
recorded. Participants will undertake a pre- and post-
training test to determine the impact of the training on
their knowledge of malaria diagnosis and treatment. All
participants will be invited to complete the training eva-
luation, which assesses the content and delivery of the
training course. In addition, the trainers will complete a
form to record any challenges faced in running the
training workshop. Finally, the process of distributing
the RDTs to health facilities will be monitored and any
problems with the procedures for replenishing RDT
stocks will be documented.
Costing
Direct and indirect costs of each phase of the interven-
tions (i.e. development, implementation, upkeep) will be
assessed from both a provider and societal perspective
using standard economic evaluation methodologies [32].
Cost data will primarily be estimated from health facility
records, project financial accounts and from the provi-
der and patient exit surveys. Any health care savings
will also be included and subtracted from costs.
Quality assurance
Data collection and management There is a quality
assurance officer responsible for ensuring all implementa-
tion and evaluation activities adhere to standard operating
procedures. Quality assurance will include monitoring the
process of obtaining consent, data collection, transfer of
completed survey instruments, data management and the
secure storage of study materials. In addition, field super-
visors will monitor the survey administration undertaken
by field workers and make frequent visits (at least once a
week) to assess the quality of data collection and review
completed questionnaires.
Only authorised staff with appropriate training will
have access to the databases to perform data entry. All
databases will be password protected. Each data form will
be entered by two data entry clerks in a database of the
same structure using two different computers. Entries
will be compared for discrepancies using the Epi info
2000 data compare utility. Any discrepancies will be cor-
rected by crosschecking against the corresponding origi-
nal questionnaire. Checks (validation rules) will be
implemented in different fields of the database. Data will
also be queried electronically to ensure the correct data
is entered under the correct variables for each section of
the form/questionnaire. A log of all data changes will be
kept. Questionnaires will be kept in a locked filing
cabinet.
Independent verification of malaria tests conducted
and test results Reliance on providers register of malaria
tests conducted and their interpretation of the test result
may be a risk for data quality. For example, we are
dependent on the providers’ skills in conducting and
interpreting the test results and the accuracy of their
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ister of malaria tests by comparing the patient reported
data on whether they had a test with the register. We will
also independently conduct RDT tests in a sub-sample of
5% of patients on exit that reported they were tested for
malaria to determine the degree of consistency between
the test result recorded by the provider and the test result
conducted by the fieldworker. In addition, a sample of
cases (both positive and negative) will be tested using
PCR to check the sensitivity and specificity of both RDT
and Microscopy. Quality assurance of the RDTs is
beyond the scope of the study.
Sample size
Patient exit survey
Sample size calculations are based on the primary out-
come, the proportion of patients that receive treatment
according to malaria treatment guidelines. Based on
results from the formative research we expect that this
will be 15% in the control arm (current practice) with a
coefficient of variation (k) within stratum of 0.3.
To evaluate the effect of each of the intervention arms
compared to current practice we have powered the
study to detect a 15% increase over the control, from
15% to 30%, which was deemed to be the minimum
increase for each of the interventions to be worthwhile.
Using methods for stratified cluster randomised trials
[33] and assuming k = 0.25 in the intervention arms, 7
clusters per arm and 100 patients per facility are
required to detect this improvement with 80% power at
a 5% significance level. With allowance for drop outs
from the trial we propose 9 facilities per arm. A lower
coefficient of variation was assumed in the intervention
arms due to the shared training.
If both intervention arms prove to be significantly bet-
ter than the control it is likely that the enhanced inter-
vention will be better than the basic intervention and
we expect a further 10% improvement in the primary
outcome, to 40%. Therefore to determine whether or
not the basic intervention should be recommended we
wish to evaluate whether it is just as effective as (i.e.
non-inferior to) the enhanced intervention. Assuming
that the largest difference between the two intervention
arms that would be considered unimportant is 10% (i.e.
non-inferiority margin) then using methods for equiva-
lence in cluster randomised trials [33] 17 clusters per
intervention arm with 100 patients per cluster are
required to have 80% power to demonstrate that the
limit of a one-sided 95% confidence interval (CI) will be
10% or less. With allowance for drop outs from the trial
we propose 19 clusters per arm.
Provider survey
The sample size calculations for the provider survey
gives the anticipated level of precision for calculating
the proportion of providers that know the treatment
guidelines (i.e. report that parasitological testing is
recommended and that ACTs are for confirmed cases of
malaria). Based on our formative research we can
assume 3-4 providers per facility, an intra-correlation
coefficient (ICC) of 0.1, and an estimate of the primary
outcome in each arm of 90%. With 9 facilities in the
control arm and 19 facilities in each of the intervention
arms this allows us to estimate the true primary out-
come with ± 11.8% precision in the control arm and ±
7.7% precision in each of the intervention arms.
Randomisation
A total of 47 facilities, 23 in Bamenda and 24 in Yaoundé,
will be randomised within stratum to receive current
practice, the basic intervention (RDTs and basic training)
or the enhanced intervention (RDTs with enhanced
training). With cluster randomised trials there is an
increased chance that the study arms are unbalanced
with respect to known and unknown potential confoun-
ders, and therefore undermines the credibility of the trial
results. Stratified randomisation will reduce the likely
imbalance in factors known to be correlated with the
study outcome and the study site. However, the current
availability of microscopy and the type of facility (which
will also capture variation in health worker and patient
characteristics) were assumed to be important correlates
and therefore a process of constrained, or restricted, ran-
domisation [34,35] will also be implemented to balance
these two factors across the study arms using data col-
lected in the formative research.
Using restricted randomisation schemes increases the
risk of producing a design which is biased and not valid.
Moulton [35] describes a design as being biased if there
is any difference across the clusters in their probability of
allocation to any given treatment. A randomised design
is said to be valid if every pair of clusters has the same
probability of being allocated to the same treatment. If
the design is not valid there is a risk that the Type I error
changes from its nominal value of 0.05. We will assess
the validity of the restricted randomisation by producing
a matrix where the rows and columns represent the clus-
ters and the elements of the matrix are the proportion of
times each pair of clusters is allocated to the same study
arm i.e. the probability that the i
th cluster is being allo-
cated to the same intervention group as the j
th cluster.
The matrix will then be examined for under- and over-
represented pairs that would highlight any potential
causes for concern in the randomisation.
Randomisation of the facilities will be performed by
the study statistician after informed consent has been
sought from the head of the facility to avoid selection
bias. Patients (or caregivers) and fieldworkers adminis-
tering the patient exit survey will be blinded to group
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ing the training interventions and supervising data col-
lection will need to be aware of which facilities receive
the different interventions.
Figure 3 shows study eligibility, selection, enrolment
and methods of data collection.
Data analysis
Initially an overall test of the null hypothesis that there
are no differences between either of the intervention
arms and the control will be performed to guard against
over-interpretation of any significant effects from indivi-
dual comparisons of each intervention with the control,
particularly if there is no evidence of a difference for
any of the intervention arms.
The effect of the two interventions compared with
control will be analysed with methods appropriate for
cluster randomised trials. Point estimates of the primary
outcome will be calculated using the unweighted mean
of the cluster summaries in each stratum. If the distri-
bution of the summary measures in each study arm is
skewed, a logarithmic transformation to the proportions
will be considered. An overall estimate of the risk ratio
will be obtained by taking a weighted average of the
stratum-specific risk ratios where the weights are inver-
sely proportional to the stratum-specific variances. 95%
confidence intervals (CI) will be adjusted for observed
between-cluster variance and formal hypothesis testing
will be conducted using stratified t-tests. Adjustment for
covariates, including patient and provider characteristics
and knowledge, contextual factors and process factors,
will be carried out using a two-stage process. In the first
stage, a logistic regression model including stratum as a
fixed effect and the covariates of interest, but excluding
the intervention effect, will be fitted to calculate cluster-
specific expected values. The ratio of observed and
expected values will be computed to give the ratio-resi-
dual for each cluster. In the second stage, the above
methods for estimating the RR and 95% CI and hypoth-
esis testing are carried out with the cluster-level propor-
tions replaced with the covariate-adjusted residuals [35].
Non-inferiority between the two intervention arms will
be assessed using the same methods as described above
but instead of the risk ratio the risk difference will be
estimated. Inference will be based solely on one-sided
95% CIs (or equivalently 2-sided 90% CIs).
Secondary outcomes on treatment received by
patients, and provider knowledge and practice, will be
analysed using the methods described above. To exam-
ine whether secondary outcomes vary according to the
urban/rural residence and socioeconomic status of the
patients methods appropriate for examining an interac-
tion between the intervention and the individual-level
variable will be applied [36]. Differences in coverage
Figure 3 Eligibility, selection, enrolment and methods of data collection.
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estimated by calculating the arithmetic mean of the cov-
erage proportions in each cluster and conducting a two-
way analysis of variance, allowing for stratification.
For the economic analysis, cost-effectiveness ratios will
be based on the primary outcome (i.e. the cost per case
of suspected malaria that received treatment as recom-
mended in the malaria guidelines) as well as a range of
secondary outcomes including changes in provider
knowledge. Cost-effectiveness will be calculated for each
comparison and will be expressed as incremental cost-
effectiveness ratios (ICERs). One-way and multi-way
sensitivity analysis will be undertaken to examine the
effects of varying uncertain variables on study findings.
Costs and effects will be presented in both discounted
and undiscounted form.
All data will be double entered using Microsoft Access
2007 (Microsoft Inc., Redmond, Washington) and ana-
lysed using STATA version 11.0 (STATA Corporation,
College Station, Texas). A full analysis plan will be
reviewed and agreed before the data are analysed.
Trial status
Patients and providers are currently being recruited into
the study for the patient exit survey.
Discussion
Results from the study will be reported at local, national
and international levels. At the local and national level,
the Research on the Economics of ACTs (REACT) Pro-
ject (http://www.actconsortium.org/pages/project-5.
html) will continue working with the Ministry of Health
after the trial is completed to adapt the most cost-effec-
tive interventions for national use. At the international
level, we also see an opportunity to support the imple-
mentation of the 2010 WHO malaria treatment guide-
lines which acknowledge the need for provider training
alongside the large-scale deployment of RDTs and
ACTs.
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